{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T10:53:06Z","timestamp":1764240786477,"version":"3.41.2"},"reference-count":8,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,13]],"date-time":"2024-09-13T00:00:00Z","timestamp":1726185600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["jaadcasereports.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JAAD Case Reports"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.jdcr.2024.08.032","type":"journal-article","created":{"date-parts":[[2024,9,19]],"date-time":"2024-09-19T09:23:30Z","timestamp":1726737810000},"page":"177-180","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Drug-induced subacute cutaneous lupus erythematosus involving osimertinib"],"prefix":"10.1016","volume":"53","author":[{"given":"Christian L.","family":"Bailey-Burke","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlos H.","family":"Nousari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael W.","family":"Wangia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.jdcr.2024.08.032_bib1","article-title":"Epidermal growth factor receptor tyrosine kinase inhibitors and lung cancer: history, epidemiology, and market outlook","volume":"13","author":"Miles","year":"2021","journal-title":"Cureus"},{"issue":"1","key":"10.1016\/j.jdcr.2024.08.032_bib2","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1186\/s13045-022-01391-4","article-title":"Therapeutic strategies for EGFR-mutated non-small cell lung cancer patients with osimertinib resistance","volume":"15","author":"Fu","year":"2022","journal-title":"J Hematol Oncol"},{"issue":"8","key":"10.1016\/j.jdcr.2024.08.032_bib3","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1634\/theoncologist.2017-0582","article-title":"Osimertinib: a novel dermatologic adverse event profile in patients with lung cancer","volume":"23","author":"Chu","year":"2018","journal-title":"Oncologist"},{"key":"10.1016\/j.jdcr.2024.08.032_bib4","article-title":"Subacute cutaneous lupus erythematosus-like eruption induced by EGFR -tyrosine kinase inhibitor in EGFR-mutated non-small cell lung cancer: a case report","volume":"8","author":"Ferro","year":"2021","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.jdcr.2024.08.032_bib5","series-title":"StatPearls [Internet]","article-title":"Drug-induced lupus erythematosus","author":"Solhjoo","year":"2023"},{"key":"10.1016\/j.jdcr.2024.08.032_bib6","doi-asserted-by":"crossref","first-page":"51","DOI":"10.2147\/CCID.S344445","article-title":"Subacute cutaneous lupus erythematosus-like eruption induced by Durvalumab: a case report and literature review","volume":"15","author":"Pratumchart","year":"2022","journal-title":"Clin Cosmet Investig\u00a0Dermatol"},{"issue":"1","key":"10.1016\/j.jdcr.2024.08.032_bib7","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1159\/000523800","article-title":"Nivolumab-induced de novo discoid lupus erythematosus","volume":"14","author":"Manjunath","year":"2022","journal-title":"Case Rep Dermatol"},{"issue":"4","key":"10.1016\/j.jdcr.2024.08.032_bib8","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.annder.2021.02.006","article-title":"Cutaneous drug-induced\u00a0lupus erythematosus: clinical and immunological characteristics\u00a0and\u00a0update on new associated drugs","volume":"148","author":"Bataille","year":"2021","journal-title":"Ann Dermatol Venereol"}],"container-title":["JAAD Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352512624003539?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352512624003539?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T23:10:42Z","timestamp":1753917042000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352512624003539"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":8,"alternative-id":["S2352512624003539"],"URL":"https:\/\/doi.org\/10.1016\/j.jdcr.2024.08.032","relation":{},"ISSN":["2352-5126"],"issn-type":[{"type":"print","value":"2352-5126"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Drug-induced subacute cutaneous lupus erythematosus involving osimertinib","name":"articletitle","label":"Article Title"},{"value":"JAAD Case Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jdcr.2024.08.032","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 by the American Academy of Dermatology, Inc. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}